Since ALCAM mRNA levels remain unaltered during tumor progression in four independent patient cohorts and fail to predict overall survival by univariable and multivariable analyses, we conclude that ALCAM gene expression is not a viable biomarker for BCa prognosis. The gene discussed is ALCAM; the disease is neoplasm.